Antibody persistence 1-5 years following vaccination with MenAfriVac in African children vaccinated at 12-23 months of age

Milagritos D. Tapia; Helen Findlow; Olubukola T. Idoko; Marie Pierre Preziosi; Prasad S. Kulkarni; Godwin C. Enwere; Cheryl Elie; Varsha Parulekar; Samba O. Sow; Fadima Cheick Haidara; Fatoumata Diallo; Moussa Doumbia; Adebayo K. Akinsola; Richard A. Adegbola; Beate Kampmann; Julie Chaumont; Lionel Martellet; Elisa Marchetti; Simonetta Viviani; Yuxiao Tang; Brian D. Plikaytis; F. Marc La Force; George Carlone; Raymond Borrow

doi:10.1093/cid/civ672

Antibody persistence 1-5 years following vaccination with MenAfriVac in African children vaccinated at 12-23 months of age

Milagritos D. Tapia^*, Helen Findlow, Olubukola T. Idoko, Marie Pierre Preziosi, Prasad S. Kulkarni, Godwin C. Enwere, Cheryl Elie, Varsha Parulekar, Samba O. Sow, Fadima Cheick Haidara, Fatoumata Diallo, Moussa Doumbia, Adebayo K. Akinsola, Richard A. Adegbola, Beate Kampmann, Julie Chaumont, Lionel Martellet, Elisa Marchetti, Simonetta Viviani, Yuxiao TangBrian D. Plikaytis, F. Marc La Force, George Carlone, Raymond Borrow

^*Corresponding author for this work

Manchester Meningococcal Reference Unit General

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

Abstract

Background. Following mass vaccination campaigns in the African meningitis belt with group A meningococcal conjugate vaccine, MenAfriVac (PsA-TT), disease due to group A meningococci has nearly disappeared. Antibody persistence in healthy African toddlers was investigated. Methods. African children vaccinated at 12-23 months of age with PsA-TT were followed for evaluation of antibody persistence up to 5 years after primary vaccination. Antibody persistence was evaluated by measuring group A serum bactericidal antibody (SBA) with rabbit complement and by a group A-specific IgG enzyme-linked immunosorbent assay (ELISA). Results. Group A antibodies measured by SBA and ELISA were shown to decline in the year following vaccination and plateaued at levels significantly above baseline for up to 5 years following primary vaccination. Conclusions. A single dose of PsA-TT induces long-term sustained levels of group A meningococcal antibodies for up to 5 years after vaccination.

Original language	English
Pages (from-to)	S514-S520
Journal	Clinical Infectious Diseases
Volume	61
DOIs	https://doi.org/10.1093/cid/civ672
Publication status	Published - 15 Nov 2015

Bibliographical note

Publisher Copyright:
© 2015 The Author. Published by Oxford University Press on behalf of the Infectious Diseases Society of America.

Keywords

African meningitis belt
MenAfriVac
antibody persistence
group A meningococcal conjugate vaccine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/cid/civ672

Cite this

Tapia, M. D., Findlow, H., Idoko, O. T., Preziosi, M. P., Kulkarni, P. S., Enwere, G. C., Elie, C., Parulekar, V., Sow, S. O., Haidara, F. C., Diallo, F., Doumbia, M., Akinsola, A. K., Adegbola, R. A., Kampmann, B., Chaumont, J., Martellet, L., Marchetti, E., Viviani, S., ... Borrow, R. (2015). Antibody persistence 1-5 years following vaccination with MenAfriVac in African children vaccinated at 12-23 months of age. Clinical Infectious Diseases, 61, S514-S520. https://doi.org/10.1093/cid/civ672

@article{bd7902b1c1d94437942f254fac00db6d,

title = "Antibody persistence 1-5 years following vaccination with MenAfriVac in African children vaccinated at 12-23 months of age",

abstract = "Background. Following mass vaccination campaigns in the African meningitis belt with group A meningococcal conjugate vaccine, MenAfriVac (PsA-TT), disease due to group A meningococci has nearly disappeared. Antibody persistence in healthy African toddlers was investigated. Methods. African children vaccinated at 12-23 months of age with PsA-TT were followed for evaluation of antibody persistence up to 5 years after primary vaccination. Antibody persistence was evaluated by measuring group A serum bactericidal antibody (SBA) with rabbit complement and by a group A-specific IgG enzyme-linked immunosorbent assay (ELISA). Results. Group A antibodies measured by SBA and ELISA were shown to decline in the year following vaccination and plateaued at levels significantly above baseline for up to 5 years following primary vaccination. Conclusions. A single dose of PsA-TT induces long-term sustained levels of group A meningococcal antibodies for up to 5 years after vaccination.",

keywords = "African meningitis belt, MenAfriVac, antibody persistence, group A meningococcal conjugate vaccine",

author = "Tapia, {Milagritos D.} and Helen Findlow and Idoko, {Olubukola T.} and Preziosi, {Marie Pierre} and Kulkarni, {Prasad S.} and Enwere, {Godwin C.} and Cheryl Elie and Varsha Parulekar and Sow, {Samba O.} and Haidara, {Fadima Cheick} and Fatoumata Diallo and Moussa Doumbia and Akinsola, {Adebayo K.} and Adegbola, {Richard A.} and Beate Kampmann and Julie Chaumont and Lionel Martellet and Elisa Marchetti and Simonetta Viviani and Yuxiao Tang and Plikaytis, {Brian D.} and {La Force}, {F. Marc} and George Carlone and Raymond Borrow",

note = "Publisher Copyright: {\textcopyright} 2015 The Author. Published by Oxford University Press on behalf of the Infectious Diseases Society of America.",

year = "2015",

month = nov,

day = "15",

doi = "10.1093/cid/civ672",

language = "English",

volume = "61",

pages = "S514--S520",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

}

Tapia, MD, Findlow, H, Idoko, OT, Preziosi, MP, Kulkarni, PS, Enwere, GC, Elie, C, Parulekar, V, Sow, SO, Haidara, FC, Diallo, F, Doumbia, M, Akinsola, AK, Adegbola, RA, Kampmann, B, Chaumont, J, Martellet, L, Marchetti, E, Viviani, S, Tang, Y, Plikaytis, BD, La Force, FM, Carlone, G & Borrow, R 2015, 'Antibody persistence 1-5 years following vaccination with MenAfriVac in African children vaccinated at 12-23 months of age', Clinical Infectious Diseases, vol. 61, pp. S514-S520. https://doi.org/10.1093/cid/civ672

TY - JOUR

T1 - Antibody persistence 1-5 years following vaccination with MenAfriVac in African children vaccinated at 12-23 months of age

AU - Tapia, Milagritos D.

AU - Findlow, Helen

AU - Idoko, Olubukola T.

AU - Preziosi, Marie Pierre

AU - Kulkarni, Prasad S.

AU - Enwere, Godwin C.

AU - Elie, Cheryl

AU - Parulekar, Varsha

AU - Sow, Samba O.

AU - Haidara, Fadima Cheick

AU - Diallo, Fatoumata

AU - Doumbia, Moussa

AU - Akinsola, Adebayo K.

AU - Adegbola, Richard A.

AU - Kampmann, Beate

AU - Chaumont, Julie

AU - Martellet, Lionel

AU - Marchetti, Elisa

AU - Viviani, Simonetta

AU - Tang, Yuxiao

AU - Plikaytis, Brian D.

AU - La Force, F. Marc

AU - Carlone, George

AU - Borrow, Raymond

PY - 2015/11/15

Y1 - 2015/11/15

N2 - Background. Following mass vaccination campaigns in the African meningitis belt with group A meningococcal conjugate vaccine, MenAfriVac (PsA-TT), disease due to group A meningococci has nearly disappeared. Antibody persistence in healthy African toddlers was investigated. Methods. African children vaccinated at 12-23 months of age with PsA-TT were followed for evaluation of antibody persistence up to 5 years after primary vaccination. Antibody persistence was evaluated by measuring group A serum bactericidal antibody (SBA) with rabbit complement and by a group A-specific IgG enzyme-linked immunosorbent assay (ELISA). Results. Group A antibodies measured by SBA and ELISA were shown to decline in the year following vaccination and plateaued at levels significantly above baseline for up to 5 years following primary vaccination. Conclusions. A single dose of PsA-TT induces long-term sustained levels of group A meningococcal antibodies for up to 5 years after vaccination.

AB - Background. Following mass vaccination campaigns in the African meningitis belt with group A meningococcal conjugate vaccine, MenAfriVac (PsA-TT), disease due to group A meningococci has nearly disappeared. Antibody persistence in healthy African toddlers was investigated. Methods. African children vaccinated at 12-23 months of age with PsA-TT were followed for evaluation of antibody persistence up to 5 years after primary vaccination. Antibody persistence was evaluated by measuring group A serum bactericidal antibody (SBA) with rabbit complement and by a group A-specific IgG enzyme-linked immunosorbent assay (ELISA). Results. Group A antibodies measured by SBA and ELISA were shown to decline in the year following vaccination and plateaued at levels significantly above baseline for up to 5 years following primary vaccination. Conclusions. A single dose of PsA-TT induces long-term sustained levels of group A meningococcal antibodies for up to 5 years after vaccination.

KW - African meningitis belt

KW - MenAfriVac

KW - antibody persistence

KW - group A meningococcal conjugate vaccine

UR - http://www.scopus.com/inward/record.url?scp=84947577511&partnerID=8YFLogxK

U2 - 10.1093/cid/civ672

DO - 10.1093/cid/civ672

M3 - Article

C2 - 26553683

AN - SCOPUS:84947577511

SN - 1058-4838

VL - 61

SP - S514-S520

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

ER -

Antibody persistence 1-5 years following vaccination with MenAfriVac in African children vaccinated at 12-23 months of age

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this